A clinical review of semaglutide 2.4 mg (Wegovy) used off-label for binge eating disorder, including trial data, risk-benefit analysis, and practical prescribing considerations.
A clinical evidence review of semaglutide 2.4 mg (Wegovy) for nonalcoholic steatohepatitis (NASH/MASH), covering phase 2 and phase 3 trial data, mechanism of action, GRADE-level assessment, and practical prescribing considerations.
Semaglutide 2.4 mg (Wegovy) is used off-label for NASH/MASH. Learn the clinical trial evidence, monitoring schedule, liver enzyme targets, and what your provider should track.
Zepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn about its off-label use for type 2 diabetes, the clinical evidence from SURPASS trials, and the monitoring your clinician should follow.
Zepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn the evidence behind off-label use for type 2 diabetes, how it compares to Mounjaro, risks, and what clinicians consider before prescribing.
A clinical evidence review of tirzepatide (Zepbound) for heart failure, covering trial data from SUMMIT and STEP-HFpEF, FDA-approved indications, and what the research shows about cardiac outcomes.
Tirzepatide (Zepbound) is not FDA-approved for heart failure. Trial evidence in HFpEF with obesity shows symptom and functional improvement, but not proven reductions in hospitalization or death. Here is what the evidence supports, what remains unproven, and what monitoring off-label use requires.
Can Zepbound (tirzepatide) treat heart failure? Review the off-label evidence from SURMOUNT-HFpEF trials, FDA-approved indications, cardiovascular risks, and what clinicians consider before prescribing.
Tirzepatide (Zepbound) is not FDA-approved for PCOS, but clinicians are using it off-label based on its weight-loss and insulin-sensitizing effects. Here is what is established, what is plausible but unproven, and what monitoring is reasonable before and during treatment.
Evidence-based guide to low-dose oral minoxidil dosing in adolescents aged 12 to 17, covering off-label use for androgenetic alopecia, starting doses, monitoring, and safety considerations.
Complete monitoring protocol for low-dose oral minoxidil in adults aged 30-49, including baseline labs, blood pressure tracking, ECG timing, echocardiogram indications, and when to adjust or stop treatment.
Low-dose oral minoxidil (0.625-5mg) is safe for most adults 30-49 at 2.5mg or below, but needs baseline blood pressure and heart rate checks before starting.
Find out whether Aetna (CVS Health) covers oral minoxidil for hair loss, including prior authorization requirements, formulary tier, step therapy, and how to appeal a denial.
Anthem (Elevance Health) coverage details for oral minoxidil prescribed for hair loss, including prior authorization requirements, formulary tier, step therapy, appeal options, and cash-pay alternatives.
A guide to food and supplement interactions with low-dose oral minoxidil for hair loss, including potassium, sodium, tyramine, and common supplements.
A clinician-focused review of low-dose oral minoxidil safety in geriatric patients (65+), covering cardiovascular risks, drug interactions, renal dosing, and monitoring protocols.
A clinical review of oral minoxidil's manufacturing origins, FDA-approved and compounded supply chains, shortage timelines, and what prescribers should know about current availability.
Complete monitoring schedule for low-dose oral minoxidil, including baseline labs, blood pressure tracking, cardiac screening, and follow-up intervals backed by clinical evidence.
Compare oral minoxidil uses for pattern hair loss, persistent shedding and scarring alopecia, with actual trial results, dosing context and treatment outcomes.
Oral minoxidil dosing after 50: published treatment doses, blood-pressure medicines, useful monitoring and how to assess hair growth over time.
A guide to oral minoxidil's regulatory standing across the US, EU, Canada, and UK, including off-label prescribing rules, compounding pathways, and low-dose hair loss use.
Oral minoxidil is a tablet (0.625-5mg daily) for hair loss, not an injectable. See how it works, dosing, onset time, and the hypertrichosis side effect risk.
How to plan a switch to or from oral minoxidil, what overlap evidence shows, and why doses, monitoring and other hair-loss medicines need an individual plan.
Complete dosing guide for low-dose oral minoxidil in young adults aged 18-29 treating androgenetic alopecia, including starting doses, titration schedules, monitoring, and safety considerations.
Ozempic is approved for adults 18 and older only. Wegovy is the semaglutide cleared from age 12, so any Ozempic use under 18 is off-label prescribing.
Complete Ozempic dosing guide for adults aged 30 to 49, covering the FDA-approved titration schedule, maintenance doses of 0.5 mg to 2.0 mg, missed-dose rules, and clinical trial outcomes from SUSTAIN and STEP programs.
Anthem (Elevance Health) covers Ozempic for type 2 diabetes with prior authorization and step therapy. Learn formulary tier placement, PA criteria, appeal options, and how to reduce out-of-pocket costs.
Complete guide to BCBS Federated coverage for Ozempic (semaglutide), including prior authorization criteria, formulary tier placement, step therapy requirements, appeal strategies, and cost-saving options.
Ozempic's 2023 list price is $935.77/month, close to Trulicity and Rybelsus but under Mounjaro. Compare costs and weight-loss results before switching.
A clinical review of Novo Nordisk's semaglutide pipeline, including oral semaglutide upgrades, CagriSema, amycretin, and next-generation GLP-1 receptor agonists in development beyond current Ozempic formulations.
Evidence-based monitoring guide for semaglutide (Ozempic) in adults 65 and older, covering renal function, sarcopenia screening, fall risk, polypharmacy review, and dose titration.
Evidence-based safety profile of Ozempic (semaglutide 0.5-2.0 mg) in adults aged 65 and older, including fall risk, renal considerations, muscle loss, and monitoring protocols.
Evidence-based guide to semaglutide (Ozempic) dosing in patients with hepatic impairment, including pharmacokinetic data, clinical trial evidence, and monitoring recommendations.
A physician-level breakdown of how Ozempic (semaglutide) works, from GLP-1 receptor binding and cAMP signaling to beta-cell insulin secretion, appetite suppression, and gastric slowing.
Find out whether Medicare Advantage plans cover Ozempic (semaglutide) for type 2 diabetes or weight loss, including formulary placement, prior-authorization criteria, step therapy, and how to appeal a denial.
A clinical review of semaglutide (Ozempic) safety in adults aged 50-64, covering cardiovascular data, GI tolerability, muscle preservation, polypharmacy risks, and monitoring guidelines.
A clinical breakdown of Novo Nordisk's semaglutide patent portfolio, key expiration dates, Paragraph IV challenges, and the realistic timeline for generic Ozempic approval.
No semaglutide product, including Ozempic, is FDA-approved for children under 12. Learn about current evidence, off-label risks, growth concerns, and what pediatric guidelines actually recommend.
Why some patients lose 15% body weight on Ozempic while others plateau at 3%. A deep look at GLP1R, TCF7L2, and other gene variants that influence semaglutide efficacy, side effects, and dosing.
FDA labeling, animal data, and clinical guidance on semaglutide use before conception, during pregnancy, and while breastfeeding. Includes washout timelines and alternative glucose-management options.
The FDA added ileus to the Ozempic label in September 2023 based on FAERS postmarketing reports; intestinal obstruction was added earlier in June 2020.
How to store Ozempic (semaglutide) pens before and after first use, what happens if Ozempic is left unrefrigerated, and how long opened pens last. FDA-cited.
Complete guide to Ozempic (semaglutide) dosing for young adults aged 18 to 29, covering escalation schedules, fertility considerations, side effects, and off-label weight management.
A clinical review of semaglutide (Ozempic) safety data relevant to adults aged 18 to 29, covering side effects, fertility, cardiovascular outcomes, and monitoring recommendations.
GHRP-2 raises GH about 25-50% more than GHRP-6 but causes less hunger; GHRP-6 stimulates strong appetite fast. Compare potency, cortisol effects, and uses.
Myostatin inhibitors block the protein that limits muscle growth, but no myostatin-targeting drug is FDA-approved for muscle building in healthy adults.
SS-31 (elamipretide) is a mitochondria-targeted peptide that binds cardiolipin to reduce oxidative stress. Review the clinical trial data, safety profile, and current regulatory status.
Evidence-based monitoring guide for bremelanotide (Vyleesi/PT-141) in adults aged 30-49, covering blood pressure tracking, nausea management, skin checks, and cardiovascular safety.
Evidence-based review of bremelanotide (Vyleesi) drug-drug interactions, including contraindicated combinations, dose adjustments, and clinical monitoring parameters for prescribers and patients.
A clinical review of bremelanotide (PT-141/Vyleesi) pipeline developments, next-generation melanocortin receptor agonists, oral and intranasal formulations under investigation, and what the evolving research means for HSDD and sexual medicine.
A clinical overview of bremelanotide (PT-141 / Vyleesi) manufacturing origins, supply chain events, FDA regulatory milestones, and shortage history from development through 2026.
Evidence-based monitoring schedule for PT-141 (bremelanotide/Vyleesi), including baseline labs, blood pressure checks, and follow-up exams required before and during therapy for HSDD.
A clinical breakdown of bremelanotide (Vyleesi/PT-141) pharmacokinetics including absorption after subcutaneous injection, distribution, hepatic metabolism, renal excretion, and factors affecting drug levels.
A clinical review of bremelanotide (Vyleesi / PT-141) regulatory approvals, rejections, and pending status across the United States, European Union, Canada, and United Kingdom.
A clinical review of bremelanotide (Vyleesi / PT-141) safety signals, FDA regulatory history, cardiovascular warnings, and post-market surveillance data for HSDD treatment.
Evidence-based guide to storing bremelanotide (Vyleesi/PT-141) correctly, including temperature requirements, reconstitution stability, shelf life data, and what happens when the cold chain breaks.
Evidence-based guide to PT-141 (bremelanotide) dosing for young adults aged 18 to 29, covering FDA-approved protocols, off-label considerations, safety monitoring, and fertility planning.
Complete guide to rapamycin (sirolimus) dosing for adults aged 30 to 49, covering off-label longevity protocols, transplant dosing, monitoring requirements, and safety considerations.
A physician-level breakdown of how rapamycin (sirolimus) works, from FKBP12 binding through mTORC1 inhibition to downstream effects on autophagy, senescence, and immune modulation.
Evidence-based guidance on what to do when you miss a dose of rapamycin (sirolimus), including timing rules for weekly off-label longevity dosing and daily transplant regimens.